ReviewJournal of fungi (Basel, Switzerland)2015
Antifungal Treatment for Pityriasis Versicolor.
Review in Journal of fungi (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 110 citations in OpenAlex.
- Early-Onset Neonatal Pityriasis Versicolor Associated With Maternal Infection: A Case Report From Uganda.Clinical case reports · 2026Article
- Article
- When Pityriasis Versicolor wears a vitiligo mask: a puzzle in an immunocompromised patient.Oxford medical case reports · 2025Article
- Pityriasis versicolor epidemiology, disease predictors, and health care utilization: Analysis of 32,679 cases in a large commercial insurance database.Journal of the American Academy of Dermatology · 2025Article
- Comparison of the Efficacies of Topical Liposomal Amphotericin B and Topical Clotrimazole in the Treatment of Pityriasis Versicolor.Dermatology practical & conceptual · 2024Article
- Case Report: Scalp pityriasis versicolor may be a neglected problem.Frontiers in pediatrics · 2024Article
- Pityriasis Versicolor-A Narrative Review on the Diagnosis and Management.Life (Basel, Switzerland) · 2023Review
- Pathogenic Drug Resistant Fungi: A Review of Mitigation Strategies.International journal of molecular sciences · 2023Review
- The potential role and mechanism of circRNA/miRNA axis in cholesterol synthesis.International journal of biological sciences · 2023Review
- Zinc and Zinc Transporters in Dermatology.International journal of molecular sciences · 2022Review
- Article
- Review
- Tinea versicolor: an updated review.Drugs in context · 2022Review
- Unveiling the structure of GPI-anchored protein of Malassezia globosa and its pathogenic role in pityriasis versicolor.Journal of molecular modeling · 2021Article
- A Review on Antifungal Efficiency of Plant Extracts Entrenched Polysaccharide-Based Nanohydrogels.Nutrients · 2021Review
- A case of anti- pityriasis versicolor therapy that preserves healthy mycobiome.BMC dermatology · 2020Article
- Fluconazole conjugated-gold nanorods as an antifungal nanomedicine with low cytotoxicity against human dermal fibroblasts.RSC advances · 2020Article
- Antifungal activity of silver nanoparticles in combination with ketoconazole against Malassezia furfur.AMB Express · 2019Article
- Phenotypic Identification and Molecular Characterization of Malassezia Spp. Isolated from Pityriasis Versicolor Patients with Special Emphasis to Risk Factors in Diyala Province, Iraq.Open access Macedonian journal of medical sciences · 2019Article
- Therapy of Skin, Hair and Nail Fungal Infections.Journal of fungi (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPityriasis versicolor (PV), also known as tinea versicolor, is caused by
methodA systematic review of literature from the PubMed database was conducted up to 30 September 2014. The search criteria were "(pityriasis versicolor OR tinea versicolor) AND treatment", with full text available and English language required.
conclusionsTopical antifungal medications are the first-line treatment for PV, including zinc pyrithione, ketoconazole, and terbinafine. In cases of severe or recalcitrant PV, the oral antifungal medications itraconazole and fluconazole may be more appropriate, with pramiconazole a possible future option. Oral terbinafine is not effective in treating PV and oral ketoconazole should no longer be prescribed. Maintenance, or prophylactic, therapy may be useful in preventing recurrent infection; however, at this time, there is limited research evaluating the efficacy of prophylactic antifungal treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.